VivoSeq
Gastroenterology

Pancreatitis, Chronic

3

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Pancreatitis, Chronic is an early-stage landscape with 3 programs across 1 company. The most active players are Glaxo Dba Glaxosmithkline.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Standard Varenicline Dosing

Mayo Clinic

Bupropion

Glaxo Dba Glaxosmithkline

Increased Varenicline Dosing

Mayo Clinic

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Withdrawn1 · 50%

Clinical Trials

Trial Activity

A Randomised, Double-Blind, Non-Inferiority Trial Comparing Microbial and Porcine Pancreatic Enzyme Replacement Therapy in Chronic Pancreatitis
Not yet recruiting·AAsian Institute of Gastroenterology, India·Phase 3·NCT07697352·134 enrolled
Smoking Cessation Treatment Escalation Among Patients With Recurrent Acute Pancreatitis and Chronic Pancreatitis
Withdrawn·MMayo Clinic·Phase 2·NCT07171112

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)